Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

enGene Therapeutics Inc. - Common Stock (NQ:ENGN)

1.755 -0.005 (-0.28%)
Streaming Delayed Price Updated: 12:56 PM EDT, Jul 29, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 199,898
Open 1.730
Bid (Size) 1.750 (2,500)
Ask (Size) 1.760 (800)
Prev. Close 1.760
Today's Range 1.710 - 1.800
52wk Range 1.400 - 12.25
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
enGene Focuses Board to Support Planned Upcoming Regulatory and Commercial Milestones
From enGene Therapeutics Inc.
Via Business Wire
News headline image
enGene Reports Second Quarter 2026 Financial Results and Provides Business Update
From enGene Therapeutics Inc.
Via Business Wire

Performance

YTD
-80.2%
-80.2%
1 Month
-1.4%
-1.4%
3 Month
-74.8%
-74.8%
6 Month
-84.2%
-84.2%
1 Year
-51.8%
-51.8%

More News

Read More
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of enGene Therapeutics Inc. - ENGN
From Pomerantz LLP
Via GlobeNewswire
News headline image
Why This Fund Made a $66 Million Bet on Damora Therapeutics Amid a 700% Surge ↗
Via The Motley Fool
News headline image
Dyne Stock Is Up 56%. Here's What a $14 Million Stake Reduction Could Mean ↗
Via The Motley Fool
News headline image
ENGN Investors Have Opportunity to Join enGene Therapeutics Inc. Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of enGene Therapeutics Inc. - ENGN
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of enGene Therapeutics Inc. - ENGN
From Pomerantz LLP
Via GlobeNewswire
News headline image
Kestra Medical Grew Revenue 63%. One Fund Still Trimmed 351,000 Shares ↗
Via The Motley Fool
Topics Regulatory Compliance
Unusual volume stocks are being observed in Monday's session. ↗
Via Chartmill
News headline image
enGene Bladder Cancer Data Shows Promise, but Durability Questions Remain ↗
Via MarketBeat
Which stocks are experiencing notable movement on Thursday? ↗
Via Chartmill
Top stock movements in today's session. ↗
Via Chartmill
There are notable gap-ups and gap-downs in today's session. ↗
Via Chartmill
Which stocks are moving before the opening bell on Thursday? ↗
Via Chartmill
News headline image
enGene Announces Updated Interim Results From LEGEND Pivotal Cohort
From enGene Therapeutics Inc.
Via Business Wire
News headline image
enGene Announces Name Change to enGene Therapeutics Inc.
From enGene Therapeutics Inc.
Via Business Wire
News headline image
This Biotech Was Quietly Bought Before a $58 Per Share Takeout ↗
Via The Motley Fool
News headline image
enGene Reports First Quarter 2026 Financial Results and Provides Business Update
From enGene Holdings Inc.
Via Business Wire
News headline image
enGene to Participate in Upcoming Investor Conferences
From enGene Holdings Inc.
Via Business Wire
News headline image
enGene to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
From enGene Holdings Inc.
Via Business Wire
News headline image
enGene Announces Expanded $125 Million Debt Facility with Hercules Capital, Inc.
From enGene Holdings Inc.
Via Business Wire
News headline image
enGene Reports Full Year 2025 Financial Results and Provides Business Update
From enGene Holdings Inc.
Via Business Wire
News headline image
enGene’s Detalimogene Selected for FDA Manufacturing Pilot Program to Support Manufacturing Readiness
From enGene Holdings Inc.
Via Business Wire
News headline image
enGene to Present at the Piper Sandler 37th Annual Healthcare Conference
From enGene Holdings Inc.
Via Business Wire

Frequently Asked Questions

Is enGene Therapeutics Inc. - Common Stock publicly traded?
Yes, enGene Therapeutics Inc. - Common Stock is publicly traded.
What exchange does enGene Therapeutics Inc. - Common Stock trade on?
enGene Therapeutics Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for enGene Therapeutics Inc. - Common Stock?
The ticker symbol for enGene Therapeutics Inc. - Common Stock is ENGN on the Nasdaq Stock Market
What is the current price of enGene Therapeutics Inc. - Common Stock?
The current price of enGene Therapeutics Inc. - Common Stock is 1.755
When was enGene Therapeutics Inc. - Common Stock last traded?
The last trade of enGene Therapeutics Inc. - Common Stock was at 07/29/26 12:56 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS